Amy Raskin, CIO at Chevy Chase Trust, joins CNBC's "Halftime Report" to detail her latest portfolio moves. Sometimes a good ...

Students learned that many of these careers can be pursued with or without a college degree. Warren County Court Judge and ...

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price target ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...

Bringing nature into every subject is not only beneficial to student wellness and learning, it can make curriculum more relatable and engaging.

Barney Saltzberg’s many picture books for children include “Arlo Needs Glasses,” about his giant goldendoodle who couldn’t ...

Valentine’s Day is a day to show love and care for those closest to you. But what do kids think the holiday is all about? FOX21 checked in with a few of them for their ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...